Tiercy Jean-Marie
Transplantation Immunology Unit, National Reference Laboratory for Histocompatibility, Department of Genetics and Laboratory Medicine, University Hospital of Geneva, University of Geneva , Geneva , Switzerland.
Front Immunol. 2014 May 19;5:216. doi: 10.3389/fimmu.2014.00216. eCollection 2014.
An increasingly larger fraction of patients with hematological diseases are treated by hematopoietic stem cells transplantation (HSCT) from HLA matched unrelated donors. Polymorphisms of HLA genes represent a major barrier to HSCT because HLA-A, -B, -C and DRB1 incompatibilities confer a higher risk of acute graft-versus-host disease (aGVHD) and mortality. Although >22 million volunteer HLA-typed donors are available worldwide, still a significant number of patients do not find a highly matched HSC donor. Because of the large haplotypic diversity in HLA-B-C associations, incompatibilities occur most frequently at HLA-C, so that unrelated donors with a single HLA-C mismatch often represent the only possible choice. The ratio of HLA-C-mismatched HSCT over the total number of transplants varies from 15 to 30%, as determined in 12 multicenter studies. Six multicenter studies involving >1800 patients have reported a 21-43% increase in mortality risk. By using in vitro cellular assays, a large heterogeneity in T-cell allorecognition has been observed. Yet the permissiveness of individual HLA-C mismatches remains poorly defined. It could be linked to the position and nature of the mismatched residues on HLA-C molecules, but also to variability in the expression levels of the mismatched alleles. The permissive C03:03-03:04 mismatch is characterized by full compatibility at residues 9, 97, 99, 116, 152, 156, and 163 reported to be key positions influencing T-cell allorecognition. With a single difference among these seven key residues the C07:01-07:02 mismatch might also be considered by analogy as permissive. High variability of HLA-C expression as determined by quantitative RT-PCR has been observed within individual allotypes and shows some correlation with A-B-C-DRB1 haplotypes. Thus in addition to the position of mismatched amino acid residues, expression level of patient's mismatched HLA-C allotype might influence T-cell allorecognition, with patients low expression-C alleles representing possible permissive mismatches.
越来越多的血液病患者接受来自人类白细胞抗原(HLA)匹配的无关供者的造血干细胞移植(HSCT)治疗。HLA基因多态性是HSCT的主要障碍,因为HLA - A、- B、- C和DRB1不相容会增加急性移植物抗宿主病(aGVHD)和死亡风险。尽管全球有超过2200万已进行HLA分型的志愿供者,但仍有相当数量的患者找不到高度匹配的造血干细胞供者。由于HLA - B - C关联中存在大量单倍型多样性,HLA - C不相容最为常见,因此单个HLA - C错配的无关供者往往是唯一可能的选择。根据12项多中心研究确定,HLA - C错配的HSCT占移植总数的比例在15%至30%之间。六项涉及1800多名患者的多中心研究报告称,死亡风险增加了21%至43%。通过体外细胞试验,观察到T细胞同种异体识别存在很大异质性。然而,单个HLA - C错配的允许性仍定义不清。它可能与HLA - C分子上错配残基的位置和性质有关,也与错配等位基因表达水平的变异性有关。允许性的C03:03 - 03:04错配的特征是在据报道影响T细胞同种异体识别的关键位置9、97、99、116、152、156和163处完全相容。由于这七个关键残基中有一个差异,C07:01 - 07:02错配也可类推视为允许性错配。通过定量逆转录聚合酶链反应(RT - PCR)确定,在个体同种异型中观察到HLA - C表达的高度变异性,并且与A - B - C - DRB1单倍型存在一定相关性。因此,除了错配氨基酸残基的位置外,患者错配的HLA - C同种异型的表达水平可能会影响T细胞同种异体识别,低表达C等位基因的患者可能存在允许性错配。